



ABN 53 075 582 740

ASX ANNOUNCEMENT

15 August 2016

Withdrawal of Intention to Call General Meeting

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, advises that CVC Limited has withdrawn its notice of intention to call a General Meeting.

FOR FURTHER INFORMATION PLEASE CONTACT:

Jack Moschakis
Legal Counsel & Company Secretary
+618 8 8354 6100
jmoshakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQX:BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

Withdrawal of Intention to Call General Meeting

TO: Bionomics Limited ACN 075 582 740 (Company)
31 Dalgleish Street, THEBARTON, SA, AUSTRALIA, 5031

FROM: CVC Limited ACN 002 700 361 (CVC)
Level 6, Gold Fields House, 1 Alfred Street, SYDNEY, NSW, AUSTRALIA, 2000

DATE: 12 August 2016

On 15 March 2016, CVC gave the required notice to the Company of its intention to call a general meeting of the Company's shareholders under section 249F of the Corporations Act 2001 (Cth) (Corporations Act).

Since the serving of the notice, CVC acknowledges that significant progress has been made by the Board in restructuring itself through:

- the appointment of David Wilson and Peter Turner as non-executive directors;
- the announced intention to resign by Graeme Kaufman; and
- other statements of intent to continue to improve governance and better engage with shareholders.

CVC welcomes the appointment of Messrs Wilson and Turner as directors of the Company and is grateful for Mr Kaufman for his decision to resign. Accordingly, CVC advises that it no longer intends to call a meeting under section 249F of the Corporations Act.

However, CVC continues to consider that Trevor Tappenden should also retire as a director and will be seeking to have a resolution in that regard put to members of the Company at the Annual General Meeting.



Alexander Beard
Director



John Hunter
Company Secretary